Related Experiment Videos
Methyldopa hepatotoxicity in pregnancy: a case report
1Department of Obstetrics and Gynaecology, Queen's University, Kingston General Hospital, Canada.
American Journal of Obstetrics and Gynecology
|January 1, 1995
Summary
Methyldopa can cause severe liver injury (hepatotoxicity), even when used for chronic hypertension. Monitoring liver enzymes after starting methyldopa is crucial for patient safety.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Methyldopa is a commonly prescribed antihypertensive medication, particularly during pregnancy.
- Chronic hypertension requires long-term management to prevent cardiovascular complications.
Observation:
- A case study details a multiparous Native woman who developed hepatotoxicity.
- Clinical signs of liver injury appeared approximately three weeks after initiating methyldopa therapy.
- Elevated liver enzymes (AST 1800 IU/L, ALT 2415 IU/L) and prolonged clotting times were noted.
Findings:
- Cessation of methyldopa led to the resolution of hepatotoxicity symptoms.
- This case highlights that methyldopa, despite its perceived safety margin, can induce serious adverse liver effects.
- The patient required therapeutic intervention for coagulation abnormalities.
Implications:
- Healthcare providers should consider methyldopa-induced hepatotoxicity in patients presenting with liver dysfunction.
- Regular monitoring of serum aminotransferase levels is recommended following the initiation of methyldopa treatment.
- This case underscores the importance of vigilant pharmacovigilance for antihypertensive drugs.